Safety warnings strengthened for finasteride and dutasteride

Updated safety advice for finasteride will warn patients about potential psychiatric effects and sexual dysfunction. Dutasteride, which is also used off-label for hair loss, will receive a precautionary warning in its patient information. Both changes affect medicines that pharmacy teams handle regularly across community and hospital settings.

What happened

Regulators have directed that safety warnings be strengthened for two 5-alpha reductase inhibitors — finasteride and dutasteride — used in the treatment of hair loss and prostate conditions. The updated advice for finasteride specifically flags potential psychiatric and sexual dysfunction risks. Dutasteride, which is licensed for benign prostatic hyperplasia but also used off-label as a hair loss treatment, will have a precautionary warning added to patient information.

Both medicines are dispensed widely. The changes mean patient-facing materials will need to reflect the updated risk profile, and pharmacy teams will be expected to counsel patients accordingly.

Why it matters

These are not obscure hospital-only medicines. Finasteride and dutasteride turn up regularly on prescription in community pharmacy. Patients picking up their first supply, or a repeat, may not have seen updated leaflets yet — and some won't read them at all without a prompt from the dispenser.

The psychiatric warning on finasteride is the more significant of the two. Mood changes, depression, and anxiety have been reported in association with the drug, and those are the kinds of effects patients don't always connect to a medicine they're taking for hair loss or prostate symptoms. They may attribute low mood to other causes. A brief, clear mention at the point of dispensing can make a real difference.

Dutasteride's off-label use for hair loss is worth flagging separately. When a patient is taking a medicine outside its licensed indication, they may not have had a formal consultation where risks were discussed in depth. They might have sourced it through a private prescription or an online clinic. That makes the precautionary warning addition relevant — pharmacy teams may need to fill information gaps that wouldn't exist if the drug were prescribed on-label.

There's also a broader counselling point here. Both drugs are contraindicated in women who are pregnant or may become pregnant, because of the risk of harm to a male foetus. That risk doesn't go away with a label update, but strengthened warnings are a reminder to check that patients understand it. For men of reproductive age, the sexual dysfunction signals matter too — affecting libido, ejaculation, or erectile function are effects that patients may not volunteer, especially if they don't know the medicine could be responsible.

GPhC exam relevance

The GPhC assessment tests applied clinical knowledge, and medicines with updated safety profiles are fair territory. For finasteride and dutasteride, the areas most likely to appear in clinical reasoning questions are:

Off-label prescribing. Dutasteride's use for hair loss sits outside its licensed indication. Pre-reg candidates should be comfortable explaining what off-label use means, what responsibilities it places on the prescriber, and how it affects the information a patient should receive.

Patient counselling. If a scenario presents a patient collecting finasteride for the first time, or asking why their mood has changed since starting it, the expected response involves recognising the psychiatric and sexual dysfunction signals and knowing how to communicate them clearly without causing unnecessary alarm.

Special populations. Both drugs carry risks in women of childbearing potential. Questions involving pregnancy risk, handling precautions for crushed or broken tablets, or advice to carers should prompt recall of this class of medicine.

Monitoring and reporting. Where safety warnings are strengthened, the Yellow Card scheme becomes relevant. Pre-reg candidates should know what constitutes a reportable adverse drug reaction and how to submit a report — or advise a patient to do so.

The exam won't test whether you read this specific regulatory update. It will test whether you can apply the underlying principles to a patient encounter.

What's next

Patient information leaflets for both drugs will be updated to reflect the new warnings. In practice, that means pharmacy teams should:

• Check that updated leaflets are included with dispensed packs when they become available
• Identify patients on long-term finasteride or dutasteride who may not have been counselled on psychiatric or sexual dysfunction risks, and consider whether a conversation is warranted
• Be ready to field questions from patients who notice the changes in their leaflets and want to know if their medicine has become more dangerous (the short answer: the risks aren't new, the warnings are)

For dutasteride specifically, it's worth being alert to patients who may be receiving it through private channels for off-label hair loss treatment, where counselling may have been lighter than in a standard NHS consultation.

Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/news/regulation/safety-warnings-strengthened-for-hair-loss-and-prostate-drugs-W7KGXCD6Z5DYJGAGZMEYJT64AI/